Investors may have more clarity on Teva's long-term outlook if the generic drug maker reaches a settlement in a big opioid case before it goes to trial in Ohio next week.

The psoriasis drug was one of 10 J&J medicines that grew double digits in the third quarter, leading the company to raise guidance for the year.

Pfizer agreed to pay $250m up front for worldwide rights to a Phase II drug that could target a broad population in cardiovascular disease. Scrip talked to Pfizer's head of internal medicine research about it.

"We're planning for success," John Thero told Scrip in an interview, where he talked about the upcoming US advisory committee meeting for Vascepa, commercial expansion plans and deflected questions about a big pharma buyout.

The company filed an sNDA with the US FDA for the triple combination, hoping to expand its current COPD indication to also include asthma.